COVID-19 Therapeutics I: Clinical Evidence Studies for the Efficacy and Safety of ATR-002 in Patients with COVID-19 (MEK-I-COV)
- Funded by Federal Ministry of Research, Technology and Space (BMFTR)
- Total publications:0 publications
Grant number: 16LW0001
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$13,915,182.87Funder
Federal Ministry of Research, Technology and Space (BMFTR)Research Location
GermanyLead Research Institution
ATRIVA Therapeutics GmbHResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified